SAB Biotherapeutics, Inc. (SABSW) — Operating Cash Flow
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$44.78M | -30.6% |
| 2024 | -$34.29M | -36.5% |
| 2023 | -$25.12M | -7.1% |
| 2022 | -$23.46M | -1280.7% |
| 2021 | $1.99M | -80.1% |
| 2020 | $10.00M | — |
| Fiscal Year | Operating Cash Flow | Change YoY |
|---|---|---|
| 2025 | -$44.78M | -30.6% |
| 2024 | -$34.29M | -36.5% |
| 2023 | -$25.12M | -7.1% |
| 2022 | -$23.46M | -1280.7% |
| 2021 | $1.99M | -80.1% |
| 2020 | $10.00M | — |